Producer Cell Line for GMP Viral Vector Packaging

The Clinical Biotechnology Centre (CBC) has recently validated a GMP-compliant recombinant adeno‑associated viral vector (rAAV) manufacturing platform process to support UK academic clients in transitioning their gene therapy programmes from research into human clinical trials. The work took over four years of intensive effort, including initial process development, iterative process optimisation and scale‑up to ensure suitability for GMP technology transfer. Critical starting and raw materials were selected and ap...